April 2012
- LRG mourns the loss of a great friend, Jeroen Pit
- GDOL Update: Speakers announced
- LRG Research Team meets in Leuven, Belgium: leaves with renewed energy & commitment to finding the cure for GIST
- Meet our new Montana local rep: Dirk Niebaum
- Cellular origin of GIST from the “good” cells’ perspective
- Alianza GIST meets in Miami
- And they’re off! 1st ‘Harness a Cure’ is a success
- NJ GIST gathering serves up support & smoothies
- NoCal GISTers meet!
- New report finds most hospital errors go unreported
- Happy Cancerversary to Brenda Bannon!
- Thomas G. Overley, 1952-2012: Toledo lawyer played guitar, sang in group
- Durham lived life with passion and pride
- Did You Hear? Did You Know?
- Arizona GISTers meet!
- Spunky Texan fought GIST bravely
- Calendar
Archive
December 2009
December 2009 clinical trials update
United States
RAD001 in combination with CP- 751,871 in patients with advanced sarcomas and other malignant neoplasms (NCT00927966)
An mTOR inhibitor (RAD001) and an IGF-1R inhibitor (CP-751,871) are combined in this phase I trial, which is now recruiting at Dana-Farber Cancer Institute (DFCI).
The entry criteria allow GIST and state that patients “...on approved tyrosine kinase inhibitors must be off therapy two weeks prior to study entry.”
This trial is for age 18 and over and might be a good option for wild-type GIST patients whose tumors test for higher levels of IGF-1R and who have exhausted other options. RAD001 (Everolimus, Afinitor) has previously been used off label and in trials for GIST. The Principal Investigator is Dr. Suzanne George.
Contact: Suzanne George at 617-632- 5204, or Dr. Richard Quek at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .
Imatinib and sunitinib in treating GIST patients (NCT00573404)
This phase I trial in resistant GIST at Vanderbilt University is now ongoing and no longer recruiting.
International
Nilotinib 800 Mg and imatinib 800 Mg for The treatment of GIST patients refractory to imatinib 400 Mg (LANGIST) (NCT00751036)
Seventeen new sites have been added to this phase III trial comparing imatinib and nilotinib in resistant GIST patients. The new sites are now recruiting in Latin America, the Republic of Korea and Thailand.
Dasatinib as first-line therapy in treating GIST patients (NCT00568750)
This phase II trial for newly diagnosed GIST patients has added 17 sites and contacts in Finland, France, Germany and Switzerland.
To view the latest clinical trials, visit: http://www.liferaftgroup.org/treat/trials.html
0 Comments